Intralesional therapy of metastatic spreading melanoma with beta-interferon
J Dtsch Dermatol Ges. 2006 Sep;4(9):743-6.
doi: 10.1111/j.1610-0387.2006.06054.x.
[Article in
English,
German]
Affiliation
- 1 Department of Dermatology, Klinikum Darmstadt, Darmstadt, Germany. stefan.rapprich@klinikum-darmstadt.de
Abstract
A 74-year-old female patient developed multiple local metastases after excision of a nodular melanoma of the left cheek. There was no regression after treatment with dacarbazine (DTIC) and radiotherapy. After treatment with intralesional interferon-beta, the metastases regressed completely. The dosage was 5 million IU interferon-beta (Fiblaferon) three times weekly with courses of two and four weeks, separated by a month. Except for local swelling and inflammation, no side effects occurred. Five years after completing therapy, the patient is still tumor-free.
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Facial Neoplasms / drug therapy*
-
Facial Neoplasms / secondary*
-
Female
-
Humans
-
Injections, Intralesional
-
Interferon-beta / administration & dosage*
-
Melanoma / drug therapy*
-
Melanoma / secondary*
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / secondary*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Interferon-beta